Download this press release (449 KB). ROSEVILLE, Minn. (June 24, 2013) — Rebiotix Inc. has announced that physicians have treated the first patients as part of the PUNCH™ CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). RBX2660 represents the first drug product in the Rebiotix Microbiota Restoration Therapy (MRT) […]
Press Releases
Rebiotix Inc. Hires Ryan Gordon as Vice President
Download this press release (336 KB). ROSEVILLE, Minn. (June 4, 2013) — Rebiotix Inc. announces that Ryan Gordon, Ph.D., has joined the organization’s leadership team as vice president of technical operations. Gordon brings more than 14 years of experience in pharmaceutical research and product development, business strategy, technical sales, and leadership to Rebiotix. He is a recognized expert in transdermal drug […]
Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
Download this press release (336 KB). ROSEVILLE, Minn. (May 1, 2013) — William “Bill” McGuire, M.D., former chairman and CEO of UnitedHealth Group, has joined the board of directors of Rebiotix Inc. The Roseville, Minn.-based biotechnology company is pioneering a practical and non-antibiotic treatment for recurrent Clostridium difficile infection (CDI) known as Microbiota Restoration Therapy (MRT). CDI has been […]